Compare Neurocrine Biosciences Inc (NBIX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Utilities Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Utilities Select Sector SPDR Fund trades at $41.15 (market cap $23.60B). The key difference: Utilities Select Sector SPDR Fund is the larger of the two by market cap, and Utilities Select Sector SPDR Fund is more actively traded (28,758,237 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| NBIX | XLU | |
|---|---|---|
Market Cap | $14.36B | $23.60B |
Volume | 1,237,180 | 28,758,237 |
Sector | Health | — |
52-Week High | $185.50 | $47.73 |
52-Week Low | $123.10 | $39.25 |
Typical Hold Time | 23 Days | 80 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
XLU trades at $41.15, down slightly by 0.02% with mixed technical signals showing a bullish moving average trend but neutral oscillators. The ETF recently hit 52-week lows amid sector-wide pressure from rising interest rates. Recent news highlights utility stocks as oversold with potential defensive appeal during market volatility.
The outlook remains cautious due to interest rate sensitivity, though oversold conditions may present opportunity for defensive positioning. Key risks include continued rate hikes and regulatory pressures, while potential upside exists if utilities regain favor as AI power demand grows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
